✦ LIBER ✦

Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis

✍ Scribed by Earl Silverman; Lynn Spiegel; David Hawkins; Ross Petty; Donald Goldsmith; Laura Schanberg; Ciaran Duffy; Paul Howard; Vibeke Strand

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 151 KB
Volume: 52
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.20861

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term safety and efficacy of etanerc

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis

✍ Daniel J. Lovell; Andreas Reiff; Olcay Y. Jones; Rayfel Schneider; James Nocton; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract ## Objective Previous studies showed that etanercept treatment in patients with polyarticular‐course juvenile rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustained for up to 2 years. The goal of our study was to provide data on safety and efficacy after 4 ye

Long-term efficacy and safety of etanerc

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial

✍ Daniel J. Lovell; Edward H. Giannini; Andreas Reiff; Olcay Y. Jones; Rayfel Schn 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

Safety and efficacy of additional course

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

✍ Edward Keystone; Roy Fleischmann; Paul Emery; Daniel E. Furst; Ronald van Vollen 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB 👁 1 views

## Abstract ## Objective To determine the safety and efficacy of additional courses of rituximab in patients with rheumatoid arthritis (RA). ## Methods An open‐label extension analysis of RA patients previously treated with rituximab was conducted. Patients who had participated in any of 3 doubl

The efficacy and safety of leflunomide i

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study

✍ J. R. Kalden; M. Schattenkirchner; H. Sörensen; P. Emery; C. Deighton; B. Rozman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract ## Objective To investigate the efficacy and safety of leflunomide beyond 2 years in a multinational, open‐label extension of 2 phase III double‐blind studies. ## Methods Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day t

A phase II, multicenter, open-label stud

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

✍ Nicolino Ruperto; Pierre Quartier; Nico Wulffraat; Patricia Woo; Angelo Ravelli; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 2 views

High-dose chemotherapy and autologous he

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy

✍ Robert J. Verburg; Aike A. Kruize; Frank H. J. van den Hoogen; Willem E. Fibbe; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views